Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) reported positive results from two Phase 3 studies of dupilumab to treat moderate to severe atopic dermatitis. Shares of the biopharmaceutical leaped $44.81 to close at $405.25.
Upbeat study results for Regeneron Pharmaceuticals
April 01, 2016 at 20:19 PM EDT
